# A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

> **NCT06131398** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 77 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AMG 355
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06131398
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2026-05-24
- **Final completion:** 2026-08-03
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06131398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06131398, "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06131398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*